Loading...

Recombinant Mouse IFN-γ (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF),
Ave. Rating
Submit a Review
Product Citations
publications
Mouse_IFN-y_RECOM_CF_1_072424
Recombinant mouse IFNγ induces cytotoxicity in L929 cells in a dose dependent manner. The ED50 of this effect is 0.5 - 3.5 ng/mL
  • Mouse_IFN-y_RECOM_CF_1_072424
    Recombinant mouse IFNγ induces cytotoxicity in L929 cells in a dose dependent manner. The ED50 of this effect is 0.5 - 3.5 ng/mL
Cat # Size Price Quantity Check Availability Save
575302 10 µg 54 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575304 25 µg 112 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575306 100 µg 229 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575308 500 µg 703 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Mouse IFN-γ, amino acids His23-Cys155 (Accession # NM_008337) was expressed in E. coli.
Molecular Mass
The 134 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 15,652 Da. The DTT-reduced and non-reduced protein migrate at approximately 13 kD by SDS-PAGE.
Purity
Purity is >98%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in 20 mM HEPES, 150 mM NaCl, 5 mM TCEP, pH 7.2.
Endotoxin Level
Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.
Concentration
10 and 25 µg sizes are bottled at 100 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Recombinant mouse IFNγ induces cytotoxicity in L929 cells in a dose dependent manner. The ED50 of this effect is 0.5 - 3.5 ng/mL
Application

Bioassay
Recommended Usage

Use when high specific biological activity is required.

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Application References

(PubMed link indicates BioLegend citation)
  1. Reynolds DS, et al. 1987. J. Immunol. 139:767. (BA)
  2. Dey S, et al. 2010. Mol. Cell. Biol. 30:2181. PubMed
  3. Sun T, et al. 2012. Proc. Natl. Acad. Sci. USA 109:E2117. PubMed
Product Citations
  1. Xiao Y, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:21. PubMed
  2. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  3. Jiang Z, et al. 2021. J Clin Invest. 131: . PubMed
  4. Castillo E, et al. 2021. J Neurochem. 159:1008. PubMed
  5. Rouanne M, et al. 2022. J Clin Invest. 132: . PubMed
  6. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
  7. Karino K, et al. 2023. Arthritis Rheumatol. 75:411. PubMed
  8. Jahanbazi Jahan-Abad A, et al. 2023. Glia. 71:633. PubMed
  9. Chen H, et al. 2022. Nat Commun. 13:7375. PubMed
  10. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  11. Wei Z, et al. 2022. Nature. 609:348. PubMed
  12. Tsukumo SI, et al. 2022. Sci Adv. 8:eabq0008. PubMed
  13. Jiang S, et al. 2022. Sci Adv. 8:eabn6027. PubMed
  14. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  15. Strine MS, et al. 2022. Cell Rep. 41:111593. PubMed
  16. Mohammadpour H, et al. 2023. Cell Rep. 42:112250. PubMed
  17. Kaur N, et al. 2023. Heliyon. 9:e14952. PubMed
  18. Greer R, et al. 2016. Nat Commun. 7:13329. PubMed
  19. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  20. Li Y, et al. 2022. J Lipid Res. :100273. PubMed
  21. Mia MM, et al. 2020. PLoS Biol. 18:e3000941. PubMed
  22. Davis B, et al. 2017. J Virol. 10.1128/JVI.00889-17. PubMed
  23. Yu Y, et al. 2020. FASEB J. 34:15417. PubMed
  24. Toulmin SA, et al. 2021. Nat Commun. 12:3993. PubMed
  25. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  26. Inoue M, et al. 2016. Nat Neurosci. 19:1599-1609. PubMed
  27. Lin H, et al. 2019. Infect Immun. 87:e00055-19. PubMed
  28. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  29. Bremser A, et al. 2015. PLoS One. 10: 0137393. PubMed
  30. Ji DX, et al. 2021. Elife. 10: . PubMed
  31. Rai P, et al. 2021. Nat Immunol. 22:312. PubMed
  32. Pereira M, et al. 2022. Cell Rep. 40:111225. PubMed
  33. Jakic B, et al. 2021. Cell Death Dis. 12:187. PubMed
  34. Wongchana W, et al. 2015. J Immunol. 195: 5337 - 5346. PubMed
  35. Miranda K, et al. 2019. Front Immunol. 10:1049. PubMed
  36. Eissa IR, et al. 2021. Int J Cancer. 149:214. PubMed
  37. Nguyen TT, et al. 2022. Sci Adv. 8:eabn8614. PubMed
  38. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  39. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
  40. Chu SY, et al. 2019. Nat Commun. 10:1524. PubMed
  41. Shepardson K, et al. 2016. MBio. 7: e00506-16. PubMed
  42. Kanemaru H, et al. 2021. iScience. 24:103067. PubMed
  43. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  44. Mohammadi N, et al. 2022. Front Cell Infect Microbiol. 11:784101. PubMed
  45. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  46. Prieto–Fernández E, et al. 2020. Front Immunol. 11:586977. PubMed
  47. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  48. Schweickert PG, et al. 2021. J Thromb Haemost. 19:161. PubMed
  49. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  50. Yu Y, et al. 2021. FASEB J. 35:e21554. PubMed
  51. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  52. Zhou X, et al. 2022. Front Pharmacol. 13:818166. PubMed
  53. Kanemaru H, et al. 2022. STAR Protoc. 3:101128. PubMed
  54. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  55. Ortiz A, et al. 2019. Cancer Cell. 35:33:00. PubMed
  56. Yang L, et al. 2019. Front Immunol. 10:2020. PubMed
  57. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
  58. Bilotta AJ, et al. 2020. Cell Mol Gastroenterol Hepatol. 1.16875. PubMed
  59. Kalliara E, et al. 2022. Front Immunol. 13:947213. PubMed
  60. Hogg SJ, et al. 2022. Clin Epigenetics. 14:96. PubMed
  61. Mantsounga CS, et al. 2022. Cell Rep. 38:110309. PubMed
  62. Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
  63. AuYeung AWK, et al. 2021. Sci Rep. 11:15290. PubMed

Antigen Details

Structure
Cytokine; dimer
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Embryonic Stem Cells
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience, Stem Cells
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID
15978 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
IFN-gamma
Specificity Alt (DOES NOT SHOW ON TDS):
IFN-γ
App Abbreviation (DOES NOT SHOW ON TDS):
BA
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 7    Revision Date: 07.24.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account